Cord blood-derived stem cell therapy is a cartilage regeneration treatment for osteoarthritis based on mesenchymal stem cells isolated and cultured from allogeneic cord blood, and is highly effective in regenerating damaged cartilage tissue such as osteoarthritis.
In addition, since the cells are obtained from the umbilical cord blood of newborns, there are no limitations based on the patient's age, which was the biggest challenge of products using the patient's own autologous cells. Our cord blood stem cell therapy is the only treatment for osteoarthritis in the world approved by the Ministry of Food and Drug Safety.
